These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures. Cristiano L; Cimini A; Moreno S; Ragnelli AM; Paola Cerù M Neuroscience; 2005; 131(3):577-87. PubMed ID: 15730864 [TBL] [Abstract][Full Text] [Related]
51. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Cimini A; Benedetti E; Cristiano L; Sebastiani P; D'Amico MA; D'Angelo B; Di Loreto S Neuroscience; 2005; 130(2):325-37. PubMed ID: 15664689 [TBL] [Abstract][Full Text] [Related]
52. Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes. Poleni PE; Bianchi A; Etienne S; Koufany M; Sebillaud S; Netter P; Terlain B; Jouzeau JY Osteoarthritis Cartilage; 2007 May; 15(5):493-505. PubMed ID: 17140817 [TBL] [Abstract][Full Text] [Related]
53. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present). Takada I; Makishima M Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687 [No Abstract] [Full Text] [Related]
54. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. Chopra B; Georgopoulos NT; Nicholl A; Hinley J; Oleksiewicz MB; Southgate J Cell Prolif; 2009 Oct; 42(5):688-700. PubMed ID: 19614673 [TBL] [Abstract][Full Text] [Related]
55. Pharmacological Blockade of PPAR Isoforms Increases Conditioned Fear Responding in the Presence of Nociceptive Tone. Gaspar JC; Okine BN; Llorente-Berzal A; Roche M; Finn DP Molecules; 2020 Feb; 25(4):. PubMed ID: 32102354 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of peroxisome proliferator-activated receptor agonists on interleukin-5-induced eosinophil differentiation. Smith SG; Hill M; Oliveria JP; Watson BM; Baatjes AJ; Dua B; Howie K; Campbell H; Watson RM; Sehmi R; Gauvreau GM Immunology; 2014 Jul; 142(3):484-91. PubMed ID: 24628018 [TBL] [Abstract][Full Text] [Related]
57. The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications. Benetti E; Patel NS; Collino M Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):273-84. PubMed ID: 21696362 [TBL] [Abstract][Full Text] [Related]
58. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Rieck M; Meissner W; Ries S; Müller-Brüsselbach S; Müller R Mol Pharmacol; 2008 Nov; 74(5):1269-77. PubMed ID: 18701617 [TBL] [Abstract][Full Text] [Related]
59. The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. Roche E; Lascombe I; Bittard H; Mougin C; Fauconnet S Cell Signal; 2014 Feb; 26(2):433-43. PubMed ID: 24172859 [TBL] [Abstract][Full Text] [Related]
60. In vitro interaction between resistin and peroxisome proliferator-activated receptor γ in porcine ovarian follicles. Rak-Mardyła A; Drwal E Reprod Fertil Dev; 2016 Mar; 28(3):357-68. PubMed ID: 25034013 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]